Key insights
- Tempus AI's Q1 earnings are expected to show revenue growth, but concerns about reimbursement rates and competition are weighing on the stock. Analysts are divided, with buy ratings tempered by hold and sell recommendations. Investors will focus on the Insights business momentum and potential Medicare cuts affecting the xR liquid biopsy test. The outcome could influence near-term sentiment on the stock.
Tempus AI Inc. reports first-quarter results today after the market close, seeking to prove that surging revenue growth can overcome mounting questions about reimbursement and competition that have sent shares tumbling from their highs.
Analysts expect the precision medicine company to post a loss of 10 cents per share, which would represent a 58% improvement from the year-ago period but marks a step backward from the fourth quarter’s four-cent loss reported in February. The company has not provided revenue guidance for the quarter.
Wall Street maintains a buy rating on the $10 billion company, with 17 analysts setting a mean price target of $72.40—implying nearly 30% upside from the current price of $55.81. Yet that optimism masks a sharp divide: 10 analysts rate the stock a buy, six recommend holding, and one rates it a sell.
EPS estimates have edged 4% lower over the past two months, though they’ve held steady over the past week. Revenue estimates have remained essentially flat across both timeframes, suggesting analysts are taking a wait-and-see approach.
What Investors Are Watching
The debate centers on three critical areas that will shape Tempus’s trajectory beyond this quarter.
First, investors will scrutinize momentum in the Insights business, which licenses clinical and molecular data to pharmaceutical companies. TD Cowen upgraded Tempus to buy in mid-April, arguing the unit "is well-positioned to accelerate growth in ’26 (and beat forecasts)" as drug makers increase spending on AI-driven research tools. The question is whether management can quantify that acceleration.
Second, reimbursement headwinds loom large. Jefferies initiated coverage with a sell rating last month, citing concerns that Tempus’s xR liquid biopsy test faces potential Medicare cuts and receives lower reimbursement than competing products. The firm also flagged questions about the company’s molecular residual disease (MRD) partnership with Personalis, which "leaves less torque to upside vs. in-house MRD peers."
Third, the sustainability of Tempus’s Data and Applications segment remains under scrutiny. Jefferies noted that opt-in agreements represent roughly 27% of total contract value and questioned the company’s reliance on related-party revenue, including a $200 million contract with Pathos. Management’s commentary on customer retention and new partnership economics will be essential.
Tempus posted revenue of $367.2 million in the fourth quarter, growing 83% year-over-year, and delivered a four-cent loss that crushed analyst expectations for a 20-cent loss. That momentum has continued into 2026, with the company announcing an expanded collaboration with Gilead Sciences in early April and earning recognition on TIME’s list of the 10 most influential health and life science companies.
Today’s report will test whether strong operational fundamentals can overcome valuation concerns and competitive pressures in an increasingly crowded AI diagnostics market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.